Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
NCT ID NCT06926478
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test whether injecting adalimumab (Humira) into the eye during Boston KPro surgery is safe for 8 patients with severe corneal damage. The study focuses on side effects and tolerability, not yet on how well it works. It is for people who have run out of other options for corneal transplants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adalimumab (Humira) injection
- What this could lead to
- If safe, this could point toward a way to reduce inflammation and improve outcomes after complex corneal implant surgery.
- What could go wrong
- This is a very early, tiny trial (8 people) focused only on short-term safety. It is not designed to prove the drug works, and unexpected side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE GRAFT FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts Eye and Ear
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye transplant showdown: which corneal procedure gives better vision?
- Promising drug tackles rare eye disease that leads to blindness
- Could a simple ingredient boost dry eye drops?
- Planned study on severe skin reactions withdrawn before starting
- Can a white blood cell booster heal a rare skin emergency?
- Scientists hunt for biomarkers to unlock rare eye disease treatments